ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) President Srdjan R. Stankovic sold 1,031 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $39.65, for a total transaction of $40,879.15. Following the completion of the sale, the president now directly owns 2,968 shares of the company’s stock, valued at $117,681.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ:ACAD traded up $0.05 during midday trading on Thursday, hitting $39.95. 675,713 shares of the stock traded hands, compared to its average volume of 1,593,715. The stock has a market capitalization of $5.77 billion, a PE ratio of -20.59 and a beta of 2.81. The business’s 50 day moving average is $36.32 and its two-hundred day moving average is $28.76. The company has a quick ratio of 6.79, a current ratio of 6.85 and a debt-to-equity ratio of 0.02. ACADIA Pharmaceuticals Inc. has a one year low of $14.01 and a one year high of $44.85.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.08. The firm had revenue of $83.21 million during the quarter, compared to the consensus estimate of $72.50 million. ACADIA Pharmaceuticals had a negative net margin of 101.45% and a negative return on equity of 70.97%. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.51) earnings per share. As a group, sell-side analysts forecast that ACADIA Pharmaceuticals Inc. will post -1.86 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. First Trust Advisors LP grew its stake in shares of ACADIA Pharmaceuticals by 16.4% during the first quarter. First Trust Advisors LP now owns 4,815,776 shares of the biopharmaceutical company’s stock worth $129,304,000 after purchasing an additional 677,051 shares during the period. Clearbridge Investments LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the first quarter worth $27,000. MetLife Investment Advisors LLC grew its stake in shares of ACADIA Pharmaceuticals by 8.4% during the first quarter. MetLife Investment Advisors LLC now owns 49,671 shares of the biopharmaceutical company’s stock worth $1,334,000 after purchasing an additional 3,852 shares during the period. Metropolitan Life Insurance Co NY grew its stake in shares of ACADIA Pharmaceuticals by 11.0% during the first quarter. Metropolitan Life Insurance Co NY now owns 35,921 shares of the biopharmaceutical company’s stock worth $964,000 after purchasing an additional 3,564 shares during the period. Finally, JGP Global Gestao de Recursos Ltda. grew its stake in shares of ACADIA Pharmaceuticals by 92.3% during the second quarter. JGP Global Gestao de Recursos Ltda. now owns 17,697 shares of the biopharmaceutical company’s stock worth $473,000 after purchasing an additional 8,494 shares during the period. Institutional investors own 94.85% of the company’s stock.
Several research firms have weighed in on ACAD. JPMorgan Chase & Co. reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday, September 10th. Zacks Investment Research downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, September 11th. Svb Leerink raised shares of ACADIA Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $21.00 to $50.00 in a research note on Friday, September 13th. BidaskClub raised shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 11th. Finally, Cantor Fitzgerald upped their price objective on shares of ACADIA Pharmaceuticals from $49.00 to $56.00 and gave the company an “overweight” rating in a research note on Monday, September 23rd. Five equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $47.87.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Featured Article: What is the CBOE Russell 2000® Volatility Index?
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.